Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study-Reference-Cited by-同舟云学术

Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study

Published:2024-08-11 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

López Muñoz Ana María^ORCID,González Flores Encarnación,Carral Maseda Alberto,Pimentel Cáceres Paola,Afonso Gómez Ruth,López López Carlos,Jimeno Maté Raquel,Reina Zoilo Juan José,Castañón López Carmen,Salgado Fernández Mercedes,Aparicio Urtasun Jorge,Asensio Martínez Elena,Martín Gómez Teresa

Funder

BAYER HISPANIA, SL

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12094-024-03630-1.pdf

Reference17 articles.

1. European Medicines Agency. Stivarga. Summary of product characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/stivarga-epar-product-information_en.pdf.

2. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (correct): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12. https://doi.org/10.1016/s0140-6736(12)61900-x.

3. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–29. https://doi.org/10.1016/s1470-2045(15)70156-7.

4. Grothey A, Cutsem EV, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H-J, Goldberg RM, Sargent DJ, Cihon F, Wagner A, Laurent D, Cupit L. Time course of regorafenib-associated adverse events in the phase III CORRECT study. J Clin Oncol. 2013;31:467. https://doi.org/10.1200/jco.2013.31.4_suppl.467.

5. Ducreux M, Petersen LN, Öhler L, Bergamo F, Metges JP, De Groot JW, Wang JY, García Paredes B, Dochy E, Fiala-Buskies S, Cervantes A, O’Connor JM, Falcone A. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational correlate study. Eur J Cancer. 2019;123:146–54. https://doi.org/10.1016/j.ejca.2019.09.015.